Nuvectis Pharma Inc NVCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Nuvectis Pharma To Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $19.84
- Day Range
- $19.02–20.18
- 52-Week Range
- $5.77–29.28
- Bid/Ask
- $7.77 / $23.00
- Shares Outstanding
- 34.39M
- Market Cap
- $666.80M
- Volume/Avg
- 301,605 / 207,541
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.nuvectis.com
Valuation
Metric | NVCT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.27 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | NVCT |
|---|---|
Quick Ratio | 9.91 |
Current Ratio | 9.92 |
Interest Coverage | — |
Quick Ratio
NVCT
Profitability
Metric | NVCT |
|---|---|
Return on Assets (Normalized) | −84.01% |
Return on Equity (Normalized) | −111.76% |
Return on Invested Capital (Normalized) | −116.10% |
Return on Assets
NVCT
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|C>%^!rW | LOCK|dF#YH | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|$JKG@mC | LOCK|bHYC | $95B | |||
| Moderna Inc MRNA | LOCK|P^##k$m | LOCK|S? | $79B | |||
| argenx SE ADR ARGX | LOCK|&s%yGX | LOCK|!< | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|y&Vf&@ | LOCK|K> | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|V^#Th>& | LOCK|@>&? | $30B | |||
| Incyte Corp INCY | LOCK|lM!$gS | LOCK|%Rp | $23B | |||
| BioNTech SE ADR BNTX | LOCK|^^!%p% | LOCK|#Ft | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|dm%yzw | LOCK|@c&c | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|dn@m&X | LOCK|SZ | $15B |